{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:53:17Z","timestamp":1790790797205,"version":"4.1.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Chemotherapy is typically administered prior to consideration of tandem [\n                      <jats:sup>225<\/jats:sup>\n                      Ac]Ac-\/[\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA-617 therapy in metastatic castration-resistant prostate cancer (mCRPC), making chemotherapy-na\u00efve patients who undergo tandem radionuclide treatment extremely rare. The genomic mechanisms dictating response and resistance to prostate-specific membrane antigen\u2013radiopharmaceutical therapy (PSMA-RPT) in this setting remain unclear. While tandem therapy is expanding for aggressive disease, baseline genomic predictors of treatment outcomes are not well defined. We present rare chemotherapy-na\u00efve mCRPC cases treated with tandem PSMA-RPT and explore their molecular characteristics through plasma circulating tumor DNA (ctDNA).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Blood samples were obtained from mCRPC patients receiving [\n                      <jats:sup>225<\/jats:sup>\n                      Ac]Ac-\/[\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA-617 therapy. Cell-free DNA (cfDNA) was isolated and analyzed using ultra-low pass whole-genome sequencing (ULP-WGS). Genome-wide copy number alterations (CNAs) and tumor fraction (TFx) were inferred with the ichorCNA algorithm.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This case series included five chemotherapy-na\u00efve patients\u2014four with baseline characterization and one with longitudinal follow-up\u2014providing a rare window into cfDNA CNAs at treatment initiation. Recurrent alterations included amplifications in chromosomes 1q, 7q, and 8q, and losses in 8p. Additional events such as 12q amplification and partial 9q gain were also observed. In Patient 5, serial cfDNA analysis demonstrated stable 8p loss and 8q gain across multiple treatment cycles, despite clinical progression, suggesting clonally persistent genomic drivers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Baseline cfDNA CNA profiling in chemotherapy-na\u00efve mCRPC reveals recurrent chromosomal imbalances\u2014particularly 8p loss and 8q gain\u2014that may represent intrinsic, stable features of advanced disease. These findings highlight the exploratory potential of cfDNA-based genomics in rare PSMA-RPT cohorts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1741080","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T05:34:36Z","timestamp":1770183276000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Genomic analysis in chemotherapy-na\u00efve prostate cancer prior to PSMA-targeted treatment"],"prefix":"10.3389","volume":"16","author":[{"given":"Mariam","family":"Amghar","sequence":"first","affiliation":[{"name":"Junior Research Group Translational Radiotheranostics, German Cancer Research Center (DKFZ)","place":["Heidelberg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mareike","family":"Roscher","sequence":"additional","affiliation":[{"name":"Service Unit Radiopharmaceuticals und Preclinical Studies, German Cancer Research Center (DKFZ)","place":["Heidelberg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Rausch","sequence":"additional","affiliation":[{"name":"Genomics Core Facility, European Molecular Biology Laboratory (EMBL)","place":["Heidelberg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilal","family":"\u00d6zg\u00fcr","sequence":"additional","affiliation":[{"name":"Genomics Core Facility, European Molecular Biology Laboratory (EMBL)","place":["Heidelberg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Bauder-W\u00fcst","sequence":"additional","affiliation":[{"name":"Junior Research Group Translational Radiotheranostics, German Cancer Research Center (DKFZ)","place":["Heidelberg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Bruchertseifer","sequence":"additional","affiliation":[{"name":"European Commission, Joint Research Centre (JRC)","place":["Karlsruhe, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Morgenstern","sequence":"additional","affiliation":[{"name":"European Commission, Joint Research Centre (JRC)","place":["Karlsruhe, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladim\u00edr","family":"Bene\u0161","sequence":"additional","affiliation":[{"name":"Genomics Core Facility, European Molecular Biology Laboratory (EMBL)","place":["Heidelberg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Kratochwil","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital","place":["Heidelberg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Bene\u0161ov\u00e1-Sch\u00e4fer","sequence":"additional","affiliation":[{"name":"Junior Research Group Translational Radiotheranostics, German Cancer Research Center (DKFZ)","place":["Heidelberg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27175730","article-title":"Prostate cancer review: genetics, diagnosis, treatment options, and alternative approaches","volume":"27","author":"Sekhoacha","year":"2022","journal-title":"Molecules"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2015.995090","article-title":"Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer","volume":"16","author":"Zhang","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s40610-017-0079-1","article-title":"Molecular mechanisms of enzalutamide resistance in prostate cancer","volume":"3","author":"Culig","year":"2017","journal-title":"Curr Mol Biol Rep"},{"key":"B4","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.clgc.2023.02.006","article-title":"Taxanes versus androgen receptor therapy as second-line treatment for castrate-resistant metastatic prostate cancer after first-line androgen receptor therapy","volume":"21","author":"Broyelle","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.urology.2017.04.062","article-title":"Predicting response and recognizing resistance: improving outcomes in patients with castration-resistant prostate cancer","volume":"109","author":"Shore","year":"2017","journal-title":"Urology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01823-6","article-title":"Real-world treatment patterns and overall survival of patients with metastatic castration-resistant prostate cancer in the US prior to PARP inhibitors","volume":"38","author":"Shore","year":"2021","journal-title":"Adv Ther"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.11.013","article-title":"Activity and adverse events of actinium-225-PSMA-617 in advanced metastatic castration-resistant prostate cancer after failure of lutetium-177-PSMA","volume":"79","author":"Feuerecker","year":"2021","journal-title":"Eur Urol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00638-1","article-title":"Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study","volume":"25","author":"Sathekge","year":"2024","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.267206","article-title":"Deescalated (225)Ac-PSMA-617 versus (177)Lu\/(225)Ac-PSMA-617 cocktail therapy: A single-center retrospective analysis of 233 patients","volume":"65","author":"Rathke","year":"2024","journal-title":"J Nucl Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"100742","DOI":"10.1016\/j.drup.2020.100742","article-title":"Taxanes in cancer treatment: Activity, chemoresistance and its overcoming","volume":"54","author":"Mosca","year":"2021","journal-title":"Drug Resist Updat"},{"key":"B12","doi-asserted-by":"publisher","first-page":"101223","DOI":"10.1016\/j.drup.2025.101223","article-title":"Novel insights into taxane pharmacology: An update on drug resistance mechanisms, immunomodulation and drug delivery strategies","volume":"81","author":"Beretta","year":"2025","journal-title":"Drug Resistance Updates"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213261","article-title":"Analysis of circulating tumor DNA to monitor metastatic breast cancer","volume":"368","author":"Dawson","year":"2013","journal-title":"New Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3519","article-title":"An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage","volume":"20","author":"Newman","year":"2014","journal-title":"Nat Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02791-w","article-title":"Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer","volume":"30","author":"Shitara","year":"2024","journal-title":"Nat Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02598-9","article-title":"ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results","volume":"29","author":"Anagnostou","year":"2023","journal-title":"Nat Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1038\/s41467-024-45475-w","article-title":"Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer","volume":"15","author":"Fonseca","year":"2024","journal-title":"Nat Commun"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00965-y","article-title":"Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors","volume":"8","author":"Adalsteinsson","year":"2017","journal-title":"Nat Commun"},{"key":"B19","first-page":"466","article-title":"Optimizing the treatment regimen for targeted alpha therapy of mCRPC with 225Ac-PSMA-617","volume":"60","author":"Bruchertseifer F","year":"2019","journal-title":"J Nucl Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.05.030","article-title":"Elucidating\u00a0prostate cancer behaviour during treatment via low-pass whole-genome sequencing of circulating tumour DNA","volume":"80","author":"Sumanasuriya","year":"2021","journal-title":"Eur Urol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03704-9","article-title":"Lutetium-177\u2013PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial","volume":"31","author":"Kwan","year":"2025","journal-title":"Nat Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1200\/JCO.2025.43.5_suppl.16","article-title":"Association of baseline and on-treatment ctDNA fraction with clinical outcomes in patients with mCRPC in the PSMAfore study of 177Lu-PSMA-617","volume":"43","author":"Bono","year":"2025","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/01.LAB.0000074889.76221.49","article-title":"Genetic evaluation of localized prostate cancer in a cohort of forty patients: gain of distal 8q discriminates between progressors and nonprogressors","volume":"83","author":"van Dekken","year":"2003","journal-title":"Lab Invest"},{"key":"B24","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1158\/1078-0432.CCR-09-1423","article-title":"Chromosome 8p deletions and 8q gains are associated with tumor progression and poor prognosis in prostate cancer","volume":"16","author":"El Gammal","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2022.10.002","article-title":"Chromosome 8q arm overexpression is associated with worse prostate cancer prognosis","volume":"41","author":"Alshalalfa","year":"2023","journal-title":"Urol Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1086\/302771","article-title":"Linkage analyses at the chromosome 1 loci 1q24-25 (HPC1), 1q42.2-43 (PCAP), and 1p36 (CAPB) in families with hereditary prostate cancer","volume":"66","author":"Berry","year":"2000","journal-title":"Am J Hum Genet"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1126\/science.274.5291.1371","article-title":"Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search","volume":"274","author":"Smith","year":"1996","journal-title":"Science"},{"key":"B28","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/gcc.2870090105","article-title":"Trisomy 7: a potential cytogenetic marker of human prostate cancer progression","volume":"9","author":"Bandyk","year":"1994","journal-title":"Genes Chromosomes Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1097\/00125817-199901000-00110","article-title":"A FISH study of trisomies 7 and 8 in prostate cancer","volume":"1","author":"Mark","year":"1999","journal-title":"Genet Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0165-4608(98)00074-0","article-title":"Chromosome 7 abnormalities in prostate cancer detected by dual-color fluorescence in situ hybridization","volume":"107","author":"Cui","year":"1998","journal-title":"Cancer Genet Cytogenet"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-020-00765-2","article-title":"Breast and prostate cancers harbor common somatic copy number alterations that consistently differ by race and are associated with survival","volume":"13","author":"Chen","year":"2020","journal-title":"BMC Med Genomics"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.13425","article-title":"Deletion of 8p is an independent prognostic parameter in prostate cancer","volume":"8","author":"Kluth","year":"2016","journal-title":"Oncotarget"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-028829","article-title":"PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase","volume":"109","author":"Chan","year":"2006","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0045(19990501)39:2<79::AID-PROS1>3.0.CO;2-2","article-title":"Comparative genomic hybridization reveals DNA copy number gains to frequently occur in human prostate cancer","volume":"39","author":"Sattler","year":"1999","journal-title":"Prostate"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2018.06.016","article-title":"The role of protein tyrosine phosphatases in prostate cancer biology","volume":"1866","author":"Nunes-Xavier","year":"2019","journal-title":"Biochim Biophys Acta (BBA)  Mol Cell Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-0455","article-title":"Castration resistance in prostate cancer is mediated by the kinase NEK6","volume":"77","author":"Choudhury","year":"2016","journal-title":"Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-021-02131-7","article-title":"Prostate tumor-induced stromal reprogramming generates Tenascin C that promotes prostate cancer metastasis through YAP\/TAZ inhibition","volume":"41","author":"Lee","year":"2022","journal-title":"Oncogene"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/nrg.2015.25","article-title":"Mechanisms underlying structural variant formation in genomic disorders","volume":"17","author":"Carvalho","year":"2016","journal-title":"Nat Rev Genet"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-genet-102209-163544","article-title":"Human copy number variation and complex genetic disease","volume":"45","author":"Girirajan","year":"2011","journal-title":"Annu Rev Genet"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-100708-204735","article-title":"Structural variation in the human genome and its role in disease","volume":"61","author":"Stankiewicz","year":"2010","journal-title":"Annu Rev Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.5083","article-title":"Integrated\u00a0CTC- and EV-based detection of PSMA protein and efficacy of 177 Lu-PSMA-617 radioligand therapy","volume":"43","author":"Arafa","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1741080\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T05:34:36Z","timestamp":1770183276000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1741080\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":41,"alternative-id":["10.3389\/fonc.2026.1741080"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1741080","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]},"article-number":"1741080"}}